The goal of this observational study is to identify proteins that can be found in the cerebrospinal fluid (CSF) of patients with grade IV brain tumors, specifically glioblastomas, and correlate these proteins with progression free survival, overall survival and performance status (functionality). All participants with high probability of glioblastoma will initially be included, final inclusion will be dependent on the definitive histopathological diagnosis of the tumor.
The main question is:
Can the researchers identify a proteomic profile in CSF from study participants with glioblastoma in association with a longer progression free survival? Participants will undergo the following procedures, that do not deviate from normal standard diagnostic care.
1. Lumbar puncture to obtain CSF. 2. Blood draw. 3. Trans-surgical tissue sample of the brain tumor. Additionally participants will be planned for follow up appointments every 3 months following the first 12 months after the surgical tumor resection.
Patients with confirmed diagnosis of glioblastoma (histopathological and molecular).
Patients who voluntarily accept participation in this study.
Patients aged 18 or older.
Patients who cannot be followed up at the Regional Hospital 'Dr. Valentin Gomez Farias' ISSSTE.
Contamination of the required sample (CSF, serum, tumor).
Patients with whom no sampling was obtained or subjects with incomplete background information.
Patients who decide to withdraw participation from the study.
Patient population includes patients who arrive at the Hospital Regional 'Dr. Valentin Gomez Farias' ISSSTE, who have a high probability of glioblastoma diagnosis, based on clinical presentation and imaging. Additionally the population includes 5 patients whose samples and information has already been stored at the Mayo Clinic Florida.
Cohort
Prospective
Not listed
Overall survival
The length of time the participants are still alive after tumor resection (initial recruitment date), including disease progression.
Progression free survival
Progression free survival is defined by the amount of time the patient lives with glioblastoma from the start of treatment (surgical resection) without progression of disease. Progression of disease is defined as follows: an increase in tumor size, or; new cancerous lesiones on imaging, or; a non-measurable increase of malignant disease (eg.: paraneoplastic syndrome).
Performance status
The Karnofsky performance status (KPS) will be used to measure the functionality of patients with cancer, and their ability to perform daily tasks. This be used this as a measurement of disease progression and to correlate different KPS with the proteomics found. The KPS scale measures patients performance on a scale from 0 to 100% with 10% intervals, 0% meaning patient deceased and 100% normal activity, without signs of disease.
Click on the lead sponsor to view all of their trials.
Univeridad Autonoma de Guadalajara
Lead sponsor
Mayo Clinic
Collaborator
Hospital Valentin Gomez Farias
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
